BiotaX Labs Overview
BiotaX has developed deep explainable AI models based on system biology that can collect, analyze, and predict multiple disease states and calculate optimal interventions supported by meta-genomic AI analysis. CustomBiome's live biotherapeutic production technology is able to isolate targeted live microbes on the strain level (TaxonAI Output) based either on their taxonomy or gene functionality. BiotaX can package these microbes as customized live biotherapeutic products to fight dysbiosis in a personalized and disease-specific way.
Cumulative Funding Raised Over Time ($)
—Jun 2021
Latest News
growth-positive
An Israeli development will replace one of the most intrusive and frightening examinations with a simple at-home test
The article discusses a new attack on machine learning where an adversary poisons a training set to harm the privacy of other users data. It also mentions that c3 Communications has started its 23rd year in business with 5 new clients. The impact on the company is growth-positive. The key theme of the article is the privacy implications of the new attack on machine learning. The key issue discussed is the potential harm to the privacy of users data. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event. The confidence level is 7 out of 10.
Customers
growth-positive
Press Release
Illumina, Inc. has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator. The company has also secured over £20 million in initial UK capital commitments, including a £10 million commitment from cornerstone investor LifeArc. The capital commitments will provide match funding to every Illumina Accelerator Cambridge graduate that secures between £500,000 up to £4 million in qualified new capital. Illumina Accelerator provides selected startups with seed investment, access to Illumina sequencing systems and reagents, business guidance, genomics expertise, and lab space. The newest companies to join Illumina Accelerators portfolio include BiotaX Labs, Broken String Biosciences, Mitra Bio, MultiplAI Health, Doloromics Inc., Flightpath Biosciences, Oshun Medical, Parallel Health, and Rubik Therapeutics. Illumina Accelerator is accepting applications for the next funding cycle.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 1 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.biotax.co/ |
Locations
Givatayim, Israel
Photos & Videos
No files yet
BiotaX Labs Business
Business models
B2B
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsCore Technology
Artificial IntelligencePlatforms & InterfacesWebTags (12)
pharma-companiesweb-platformhealth-informationdigital-healthcarepersonalizationmicrobiomehospitalsbiopharmaceuticalgenomicsartificial-intelligencediagnosticsmedical-technologiesBiotaX Labs Financials
Undisclosed
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Seed
Funding stage
1
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
—Jun 2021
Private Equity Funding
Seed
Jun 2021
Undisclosed
First In Ventures, Drive Technion, ZORA Ventures
BiotaX Labs Lifecycle
Cumulative Funding Raised Over Time
—Jun 2021
All Events
Seed
Jun 2021
Undisclosed
First In Ventures, Drive Technion, ZORA Ventures
BiotaX Labs News
2 articles
growth-positive
An Israeli development will replace one of the most intrusive and frightening examinations with a simple at-home test
The article discusses a new attack on machine learning where an adversary poisons a training set to harm the privacy of other users data. It also mentions that c3 Communications has started its 23rd year in business with 5 new clients. The impact on the company is growth-positive. The key theme of the article is the privacy implications of the new attack on machine learning. The key issue discussed is the potential harm to the privacy of users data. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event. The confidence level is 7 out of 10.
Customers
growth-positive
Press Release
Illumina, Inc. has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator. The company has also secured over £20 million in initial UK capital commitments, including a £10 million commitment from cornerstone investor LifeArc. The capital commitments will provide match funding to every Illumina Accelerator Cambridge graduate that secures between £500,000 up to £4 million in qualified new capital. Illumina Accelerator provides selected startups with seed investment, access to Illumina sequencing systems and reagents, business guidance, genomics expertise, and lab space. The newest companies to join Illumina Accelerators portfolio include BiotaX Labs, Broken String Biosciences, Mitra Bio, MultiplAI Health, Doloromics Inc., Flightpath Biosciences, Oshun Medical, Parallel Health, and Rubik Therapeutics. Illumina Accelerator is accepting applications for the next funding cycle.
InvestmentExpand
BiotaX Labs Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 10 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
BiotaX Labs Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | video or image, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 516166535 |
| Crunchbase | biotax |
| Phone | +972544386721 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-15T00:00:00.000Z |
| Created | 2020-05-02T00:00:00.000Z |